CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	9 Months Ended
	May. 31, 2015	May. 31, 2014
Cash flows from operating activities
Net income	$ 3,351,558	$ 2,802,568
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation and amortization of property and equipment	168,585	35,730
Amortization of capitalized computer software development costs	748,730	584,237
Amortization of Intellectual property	566,250	30,625
Stock-based compensation	230,501	103,498
Deferred income taxes	377,666	1,349,585
(Increase) decrease in
Accounts receivable	(1,347,791)	(1,229,485)
Revenues in excess of billings	(368,170)	0
Prepaid income taxes	748,359	(644,945)
Prepaid expenses and other assets	7,106	72,993
Increase (decrease) in
Accounts payable	(56,838)	31,345
Accrued payroll and other expenses	(357,397)	38,255
Accrued bonus	(48,000)	30,000
Billings in excess of revenues	(253,318)	0
Accrued income taxes	178,894	0
Other liabilities	(14,895)	(14,894)
Deferred revenue	11,796	145,444
Net cash provided by operating activities	3,943,036	3,334,956
Cash flows from investing activities
Purchases of property and equipment	(35,620)	(21,339)
Purchases of intellectual property	0	(2,500,000)
Cash used to purchase Cognigen	(2,080,000)	0
Cash received in acquisition	190,184	0
Capitalized computer software development costs	(976,350)	(1,051,700)
Net cash provided by (used in) investing activities	(2,901,786)	(3,573,039)
Cash flows from financing activities
Payment of Dividends	(2,528,416)	(2,258,688)
Payments on Contracts Payable	(750,000)	0
Proceeds from the exercise of stock options	50,833	75,445
Net cash (used in) financing activities of continuing operations	(3,227,583)	(2,183,243)
Net increase (decrease) in cash and cash equivalents	(2,186,333)	(2,421,326)
Cash and cash equivalents, beginning of year	8,614,929	10,179,298
Cash and cash equivalents, end of period	6,428,596	7,757,972
Supplemental disclosures of cash flow information
Interest paid	0	0
Income taxes paid	320,707	572,192
Non-Cash Investing and Financing
Stock issued for acquisition of Cognigen Corporation	3,277,170	0
Creation of contract liability for acquisition of Cognigen Corporation	1,854,404	0
Purchase of intellectual property with shares and notes payable	$ 0	$ 3,500,000